Alkermes plc.(ALKS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ALKS Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Alkermes plc. (ALKS), a Healthcare sector company. ALKS is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Alkermes plc. reports quarterly revenue of $392.9M, net income of $-66.5M, free cash flow of $-169.8M. Top institutional holders of ALKS by reported 13-F value include BlackRock,, BAKER BROS. ADVISORS, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. ALKS trades on the Nasdaq exchange and files with the SEC under CIK 1520262. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALKS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Alkermes plc. directly from SEC EDGAR.
Revenue
Q1 2026
$392.9M
Net Income
Q1 2026
$-66.5M
Free Cash Flow
Q1 2026
$-169.8M
D/E Ratio
Q1 2026
0.89
Get alerted when ALKS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Alkermes plc. including:
Top Institutional Holders of ALKS
BlackRock, Inc.
$1.0B28,314,410 shBAKER BROS. ADVISORS LP
$354.0M10,012,267 shVANGUARD PORTFOLIO MANAGEMENT LLC
$336.3M9,511,112 shSTATE STREET CORP
$334.7M9,465,286 shVANGUARD CAPITAL MANAGEMENT LLC
$262.6M7,427,397 shRENAISSANCE TECHNOLOGIES LLC
$217.8M6,160,428 shAMERICAN CENTURY COMPANIES INC
$214.7M6,072,103 shDIMENSIONAL FUND ADVISORS LP
$159.9M4,522,378 shCommodore Capital LP
$148.5M4,200,000 shGEODE CAPITAL MANAGEMENT, LLC
$147.9M4,182,267 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $1.0B | 28,314,410 |
| BAKER BROS. ADVISORS LP | $354.0M | 10,012,267 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $336.3M | 9,511,112 |
| STATE STREET CORP | $334.7M | 9,465,286 |
| VANGUARD CAPITAL MANAGEMENT LLC | $262.6M | 7,427,397 |
| RENAISSANCE TECHNOLOGIES LLC | $217.8M | 6,160,428 |
| AMERICAN CENTURY COMPANIES INC | $214.7M | 6,072,103 |
| DIMENSIONAL FUND ADVISORS LP | $159.9M | 4,522,378 |
| Commodore Capital LP | $148.5M | 4,200,000 |
| GEODE CAPITAL MANAGEMENT, LLC | $147.9M | 4,182,267 |
More Healthcare Companies
View all Healthcare →Put ALKS on your watchlist
Track score changes the day Alkermes plc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ALKS a good stock to buy?
13F Pro's AI-powered analysis of Alkermes plc. (ALKS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ALKS are available on the ALKS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ALKS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ALKS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Alkermes plc.'s investment landscape.